Bio-Techne Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Bio-Techne Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Bio-Techne Corporation (NASDAQ:TECH) defied analyst predictions to release its quarterly results, which were ahead of market expectations. Results were good overall, with revenues beating analyst predictions by 3.6% to hit US$303m. Statutory earnings per share (EPS) came in at US$0.31, some 7.6% above whatthe analysts had expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Bio-Techne Corporation(納斯達克股票代碼:TECH)無視分析師的預期,公佈了超出市場預期的季度業績。總體業績良好,收入比分析師的預期高出3.6%,達到3.03億美元。法定每股收益(EPS)爲0.31美元,比分析師的預期高出約7.6%。對於投資者來說,這是一個重要時刻,因爲他們可以在報告中追蹤公司的業績,看看專家對明年的預測,看看對該業務的預期是否有任何變化。因此,我們收集了最新的業績後預測,以了解估計對明年的預測。
Taking into account the latest results, the consensus forecast from Bio-Techne's twelve analysts is for revenues of US$1.25b in 2025. This reflects a decent 8.2% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to rise 8.1% to US$1.40. In the lead-up to this report, the analysts had been modelling revenues of US$1.25b and earnings per share (EPS) of US$1.42 in 2025. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
考慮到最新業績,Bio-Techne的十二位分析師的共識預測是,2025年收入爲12.5億美元。這表明與過去12個月相比,收入增長了8.2%。預計每股法定收益將增長8.1%,至1.40美元。在本報告發布之前,分析師一直在模擬2025年收入爲12.5億美元,每股收益(EPS)爲1.42美元。鑑於他們的估計沒有重大變化,共識分析師似乎沒有在這些結果中看到任何會改變他們對業務看法的內容。
It will come as no surprise then, to learn that the consensus price target is largely unchanged at US$83.64. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Bio-Techne analyst has a price target of US$95.00 per share, while the most pessimistic values it at US$65.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
因此,得知共識目標股價基本保持不變爲83.64美元也就不足爲奇了。但是,固定單一價格目標可能是不明智的,因爲共識目標實際上是分析師目標股價的平均值。因此,一些投資者喜歡查看估計範圍,看看對公司的估值是否有任何分歧。最樂觀的Bio-Techne分析師將目標股價定爲每股95.00美元,而最悲觀的分析師則將其估值爲65.00美元。如你所見,分析師對該股的未來並不完全一致,但估計範圍仍然相當狹窄,這可能表明結果並非完全不可預測。
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's pretty clear that there is an expectation that Bio-Techne's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 6.5% growth on an annualised basis. This is compared to a historical growth rate of 12% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 6.5% annually. So it's pretty clear that, while Bio-Techne's revenue growth is expected to slow, it's expected to grow roughly in line with the industry.
從現在的大局來看,我們可以理解這些預測的方法之一是看看它們如何與過去的業績和行業增長預期相比較。很明顯,預計Bio-Techne的收入增長將大幅放緩,預計到2025年底的收入按年計算將增長6.5%。相比之下,過去五年的歷史增長率爲12%。將其與業內其他有分析師報道的公司並列,預計這些公司的收入(總計)每年將增長6.5%。因此,很明顯,儘管Bio-Techne的收入增長預計將放緩,但預計其增長將與行業大致持平。
The Bottom Line
底線
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
最明顯的結論是,該業務的前景最近沒有重大變化,分析師的收益預測保持穩定,與先前的估計一致。他們還重申了收入預期,預計該公司的增長速度將與整個行業大致相同。共識目標股價沒有實際變化,這表明該業務的內在價值與最新估計相比沒有發生任何重大變化。
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Bio-Techne going out to 2026, and you can see them free on our platform here.
根據這種思路,我們認爲該業務的長期前景比明年的收益重要得多。我們對Bio-Techne的預測將持續到2026年,你可以在我們的平台上免費查看。
Plus, you should also learn about the 2 warning signs we've spotted with Bio-Techne .
另外,你還應該了解我們在Bio-Techne中發現的兩個警告信號。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。